2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: View All • a b c d e f g h i j k l m n [o] p q r s t u v w x y z

Abstract Number: 60

O-Linked N-Acetylglucosamine Modified Proteome Of Human Osteoarthritic Cartilage: Biological Significance
Abstract Number: 1663

Obese Polymyalgia Rheumatica Patients Experience More Pain and Disability and Need Higher Doses Of Glucocorticoids
Abstract Number: 1074

Obesity and Life-Space Mobility Among Older Mexican Americans With and Without Arthritis
Abstract Number: 1589

Obesity and Vascular Factors May Play a Role In Persistent Depression Among Individuals With Systemic Lupus Erythematosus
Abstract Number: 2817

Objective Assessment Of Musculoskeletal Physical Examination Skills During Continuing Education Programs For Primary Care Providers Adds Significant Information Not Obtained Through Self-Assessment
Abstract Number: 1979

Occupational Balance Questionnaire: From People’s Perspectives To A Patient Reported Outcome
Abstract Number: 1611

Off-Label Use Of Rituximab For Systemic Lupus Erythematosus in Europe: Limited Use Mostly In Refractory Patients
Abstract Number: 1822

Oleanolic Acid Acetate Inhibits Osteoclast Differentiation By Downregulating Phospholipase Cγ² –calcium ion oscillation-Nuclear Factor Of Activated T Cell c1 Signaling, and Suppresses Bone Loss In Mice
Abstract Number: 83

Oleuropein Or Rutin Consumption Decreases The Spontaneous Development Of OA In Hartley Guinea Pig
Abstract Number: 2660

Omega-3 Supplement Use Is Associated With a Reduced Risk Of Anti-Cyclic Citrullinated Protein Positivity In a Population Without Rheumatoid Arthritis, But At Risk For Future Disease
Abstract Number: 226

Omeract Definitions For The Sonographic Appearance Of The Normal Pediatric Joint
Abstract Number: 2850

Once Daily Controlled-Release Pregabalin In Fibromyalgia Patients: A Phase 3 Double-Blind, Randomized Withdrawal, Placebo-Controlled Study
Abstract Number: 1006

One-Year Change Of Employment and Work Productivity In Patients With Systemic Lupus Erythematosus From The Southeastern United States
Abstract Number: 2518

Only BAFF mRNA, Not BAFF Protein Level In Blood, Is Associated With SLE Activity Over One Year
Abstract Number: 16

Only IgG and IgA β₂glycoprotein I Antibody Isotypes Are Associated With Venous Thrombosis In Systemic Lupus Erythematosus
Abstract Number: 2291

Only Rheumatoid Factor-Positive Subset Of Anti-Citrullinated Peptide/Protein Antibody-Negative Rheumatoid Arthritis Seroconverts To Anti-Citrullinated Peptide/Protein Antibody-Positive
Abstract Number: 1824

ONO-4059 – A Novel Small Molecule Dual Inhibitor Of Bruton’s Tyrosine Kinase (Btk) and Tec Kinase- Suppresses Osteoclastic Bone Resorption and Inflammation
Abstract Number: 1110

Onychopathy: When Ultrasound Can Help The Dermatologist
Abstract Number: 1023

Openness To and Preference For Biologic Therapy Among Patients With Rheumatoid Arthritis Prior To Biologic Initiation: Patient and Prescriber Perspectives
Abstract Number: 785

Ophthalmic Manifestations Of IgG4-Related Disease: A Single-Center Experience
Abstract Number: 2446

Opiate Use In Patients With Ankylosing Spondylitis
Abstract Number: 1126

Opportunistic Computed Tomography Screening For Determining Osteoporosis In Patients With Ankylosing Spondylitis and Spine Fractures
Abstract Number: 1344

Optimal Rheumatoid Arthritis Patient Selection For Biological Treatment From Pharmacoeconomic Perspectives Based On The Institute Of Rheumatology, Rheumatoid Arthritis (IORRA) Cohort
Abstract Number: 365

Oral Calcium Supplementation Is Associated With Subclinical Atherosclerosis In Rheumatoid Arthritis
Abstract Number: 574

Oral Candidiasis in Systemic Lupus Erythematosus
Abstract Number: 2334

ORAL SCAN: Effects Of The Oral JAK Inhibitor Tofacitinib In Combination With Methotrexate On Patient Reported Outcomes In a 24-Month Phase 3 Trial Of Active Rheumatoid Arthritis
Abstract Number: 2278

Ordering Of Serologic Markers Of Rheumatoid Arthritis Among Primary Care and Subspecialty Providers: Under-Utilization Of Anti-Citrullinated Peptide Antibody Tests By Non-Rheumatologists
Abstract Number: 1793

Oskira-1: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To Methotrexate
Abstract Number: 455

Oskira-2: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To Disease-Modifying Antirheumatic Drugs
Abstract Number: 456

Oskira-3: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To a Tumor Necrosis Factor -á Antagonist
Abstract Number: 2011

Osseous Sarcoidosis: Clinical Presentation, Treatment, and Outcomes. Experience From a Large Tertiary Care Academic Hospital
Abstract Number: 2131

Osteoarthritis Pain: Variability and Clinical Correlations
Abstract Number: 1825

Osteoclast Progenitors, Fibroblast-Like Cells and Draining Lymph Node Cells Induce Catecholaminergic-To-Cholinergic Transition Of Sympathetic Nerve Fibers Under Healthy Conditions But Not In Highly Inflamed Arthritic Tissue
Abstract Number: 1839

Osteoclastogenesis Is Enhanced By Synovial Fluid Derived Anti-Citrullinated Proteins Antibodies In Rheumatoid Arthritis
Abstract Number: 700

Osteoporosis and Fracture Risk In Outpatients With Systemic Sclerosis
Abstract Number: 1232

Osteoporosis In Rheumatoid Arthritis – Still a Threat In The Biologic Era?
Abstract Number: 1243

Osteoporosis Medication Adherence: Reasons For Stopping and Not Starting
Abstract Number: 379

Osteoporotic Fracture and Post-Operative Clinical and Cost Outcomes In Rheumatoid Arthritis: Results From Two UK Inception Cohorts
Abstract Number: 1322

Osteoprotegerin and TNF-Related Apoptosis Inducing Ligand Are Respectively Predictive Factors Of Remission and Erosion In Early Rheumatoid Arthritis Patients Included In The French Cohort Espoir
Abstract Number: 783

Outcome In Patients With Rheumatoid Disease: Simple Screening Tools Predict Cardiovascular Events and Death
Abstract Number: 2009

Outcome Of Allopurinol Or Febuxostat Treatment In Gout Patients Naïve To Urate-Lowering Therapy
Abstract Number: 2003

Outcome Of Gout Patients Placed On Febuxostat After Failing To Reach Serum Urate Target With Allopurinol
Abstract Number: 2899

Outcome Of Incidental Silent Strokes In Systemic Lupus Erythematosus
Abstract Number: 754

Outcome Of Kidney Transplantation In Paediatric Patients With ANCA Associated Glomerulonephritis: A Single-Center Experience
Abstract Number: 1236

Outcomes and Costs Of Sacral Insufficiency Fractures
Abstract Number: 356

Outcomes Of Patients With Rheumatoid Arthritis and Comorbid Hyperlipidemia
Abstract Number: 1928

Outcomes Of The Fast-Track Pathway In Giant Cell Arteritis: A Sight Saver
Abstract Number: 975

Outcomes-Based Program Evaluation Of a Musculoskeletal Ultrasound Curriculum
Abstract Number: 1255

Ovarian Dysfunction In Adult Childhood-Onset Systemic Lupus Erythematosus Patients: A Possible Role Of Methotrexate?
Abstract Number: 2652

Ovarian Reserve In Women With Primary Antiphospholipid Syndrome
Abstract Number: 199

Overcoming The Barriers To Adequate Hydroxychloroquine Retinal Toxicity Screening
Abstract Number: 43

Overexpression Of Lamin A In Mesenchymal STEM CELLS Compromises Chondrogenesis and Enhances Adipogenesis
Abstract Number: L8

Overexpression of Set1 at the Promoter Contributes to cAMP Response Element Modulator Alpha Overexpression in Systemic Lupus Erythematosus
Abstract Number: 1606

Overview Of The Safety Of Epratuzumab In Systemic Lupus Erythematosus
Abstract Number: 1859

OX40⁺ T Cells and OX40L⁺ B Cells Accumulate In The Inflamed Joints and OX40 Signalling Is Skewed Towards Autoreactivity
Abstract Number: 2076

Oxidation Products Of Arachidonic Acid and Linoleic Acid Are Increased In High Density Lipoprotein From Patients With Dermatomyositis and Polymyositis
Abstract Number: 1160

Oxidative Stress As a Disease Marker and Therapeutic Target In Patients With Tumor Necrosis Factor Receptor Associated Periodic Fever Syndrome
Abstract Number: 662

Oxidative Stress-Dependent Activation Of Collagen Synthesis Is Induced In Human Pulmonary Vascular Smooth Muscle Cells By Scleroderma Sera and Predicts Pulmonary Vascular Disease

Jump to: View All • a b c d e f g h i j k l m n [o] p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].